Commentary on Mobley and Others: Importance of Assumptions About VTE Mortality in Modeling the Cost-effectiveness of Osteoporosis Therapies

Abstract

Get full access to this article

View all access options for this article.

References

Mobley LR , Hoerger TJ , Wittenborn JS , Galuska DA , Rao JK . Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making. 2006;26:194–206.

Kanis JA , Borgstrom F , Johnell O , Oden A , Sykes D , Jonsson B. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int. 2005;16:15–25.

Mullins CD , Ohsfeldt RL . Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm. 2003;9:150–158.

Armstrong K , Chen TM , Albert D , Randall TC , Schwartz JS . Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol. 2001;98:996–1003.

Stevenson M , Lloyd Jones M , De Nigris E , Brewer N , Davis S , Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9:1–60.

Ettinger B , Black DM , Mitlak BH , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–645.

Delmas PD , Ensrud KE , Adachi JD , et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609–3617.

Grady D , Ettinger B , Moscarelli E , et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104:837–844.

Martino S , Disch D , Dowsett SA , Keech CA , Mershon J. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441–1452.

10.

Cauley J , Norton L , Lippman ME , et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125–134.

11.

Cummings S , Eckert S , Krueger K , et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 1999;281:2189–2197.

12.

Heit JA , Silverstein MD , Mohr DN , et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452–463.

13.

Douketis JD , Kearon C , Bates S , Duku EK , Ginsberg JS . Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458–462.

14.

Carson JL , Kelley MA , Duff A , et al. The clinical course of pulmonary embolism. N Engl J Med 1992;326:1240–1245.

15.

van Beek EJ , Kuijer PM , Buller HR , Brandjes DP , Bossuyt PM , ten Cate JW . The clinical course of patients with suspected pulmonary embolism. Arch Intern Med 1997;157:2593–2598.

16.

Evista Package Insert. 2001. Indianapolis, IN: Eli Lilly.

17.

Barrett-Connor E , Mosca L , Collins P , et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–137.

18.

Martino S , Cauley JA , Barrett-Connor E , et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–1761.

19.

Vogel V , Costantino J , Wickerham D , et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727–2741.